Aurinia Pharmaceuticals Stock Performance
| AUPH Stock | USD 4.91 0.09 1.80% |
The firm shows a Beta (market volatility) of 0.43, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aurinia Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aurinia Pharmaceuticals is expected to be smaller as well. Aurinia Pharmaceuticals has an expected return of -0.66%. Please make sure to confirm Aurinia Pharmaceuticals potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Aurinia Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aurinia Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in May 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Actual Historical Performance (%)
One Day Return (0.79) | Five Day Return (0.40) | Year To Date Return (42.79) | Ten Year Return 28.21 | All Time Return 28.21 |
Last Split Factor 1:50 | Last Split Date 2013-10-23 |
1 | Esperion Therapeutics Expected to Beat Earnings Estimates Can the Stock Move Higher | 02/13/2024 |
2 | Acquisition by Peter Greenleaf of 661538 shares of Aurinia Pharmaceuticals subject to Rule 16b-3 | 02/20/2024 |
3 | Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program | 02/29/2024 |
4 | Aurinia Pharma Cheaper Now, But Buyout Hopes Dashed - Seeking Alpha | 03/05/2024 |
5 | Disposition of 57745 shares by Stephen Robertson of Aurinia Pharmaceuticals at 5.6 subject to Rule 16b-3 | 03/06/2024 |
6 | Aurinia Pharmaceuticals Inc. Short Interest Down 28.2 percent in February - MarketBeat | 03/14/2024 |
7 | Disposition of 15867 shares by Scott Habig of Aurinia Pharmaceuticals at 5.48 subject to Rule 16b-3 | 03/18/2024 |
8 | Acquisition by Knappertz Volker of 256892 shares of Aurinia Pharmaceuticals subject to Rule 16b-3 | 03/22/2024 |
9 | Aurinia Will Attend 2024 Bloom Burton Co. Healthcare Investor Conference | 04/09/2024 |
10 | UPDATE New Aurinia Presentation Details at the 2024 Bloom Burton Co. Healthcare Investor Conference | 04/16/2024 |
| Begin Period Cash Flow | 94.2 M |
Aurinia |
Aurinia Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 788.00 in Aurinia Pharmaceuticals on January 18, 2024 and sell it today you would lose (297.00) from holding Aurinia Pharmaceuticals or give up 37.69% of portfolio value over 90 days. Aurinia Pharmaceuticals is currently does not generate positive expected returns and assumes 3.9483% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Aurinia, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aurinia Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aurinia Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aurinia Pharmaceuticals, and traders can use it to determine the average amount a Aurinia Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1678
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AUPH |
Estimated Market Risk
| 3.95 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.66 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aurinia Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aurinia Pharmaceuticals by adding Aurinia Pharmaceuticals to a well-diversified portfolio.
Aurinia Pharmaceuticals Fundamentals Growth
Aurinia Stock prices reflect investors' perceptions of the future prospects and financial health of Aurinia Pharmaceuticals, and Aurinia Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aurinia Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.53) % | ||||
| Current Valuation | 476.11 M | ||||
| Shares Outstanding | 144.62 M | ||||
| Price To Earning | (4.83) X | ||||
| Price To Book | 1.95 X | ||||
| Price To Sales | 4.20 X | ||||
| Revenue | 175.51 M | ||||
| Gross Profit | 83.38 M | ||||
| EBITDA | (71.67 M) | ||||
| Net Income | (78.02 M) | ||||
| Cash And Equivalents | 391.51 M | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 97.61 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 13.09 X | ||||
| Book Value Per Share | 2.63 X | ||||
| Cash Flow From Operations | (33.46 M) | ||||
| Earnings Per Share | (0.54) X | ||||
| Market Capitalization | 728.87 M | ||||
| Total Asset | 548.06 M | ||||
| Retained Earnings | (942.32 M) | ||||
| Working Capital | 347.61 M | ||||
| Current Asset | 16.53 M | ||||
| Current Liabilities | 3.62 M | ||||
About Aurinia Pharmaceuticals Performance
To evaluate Aurinia Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Aurinia Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Aurinia Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Aurinia Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Aurinia's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1 K | 707 | |
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (0.21) | (0.22) |
Things to note about Aurinia Pharmaceuticals performance evaluation
Checking the ongoing alerts about Aurinia Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aurinia Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aurinia Pharmaceuticals generated a negative expected return over the last 90 days | |
| Aurinia Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 175.51 M. Net Loss for the year was (78.02 M) with profit before overhead, payroll, taxes, and interest of 83.38 M. | |
| Aurinia Pharmaceuticals currently holds about 391.51 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Aurinia Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from businesswire.com: UPDATE New Aurinia Presentation Details at the 2024 Bloom Burton Co. Healthcare Investor Conference |
- Analyzing Aurinia Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aurinia Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Aurinia Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aurinia Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aurinia Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aurinia Pharmaceuticals' stock. These opinions can provide insight into Aurinia Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Aurinia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.225 | Quarterly Revenue Growth 0.586 | Return On Assets (0.11) | Return On Equity (0.20) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.